M&A Deal Summary

Chiesi Farmaceutici Acquires Raptor Pharmaceuticals

On May 23, 2017, Chiesi Farmaceutici acquired life science company Raptor Pharmaceuticals from Horizon Therapeutics for 70M USD

Acquisition Highlights
  • This is Chiesi Farmaceutici’s 3rd transaction in the Life Science sector.
  • This is Chiesi Farmaceutici’s 2nd largest (disclosed) transaction.
  • This is Chiesi Farmaceutici’s 1st transaction in the United States.
  • This is Chiesi Farmaceutici’s 1st transaction in California.

M&A Deal Summary
Date 2017-05-23
Target Raptor Pharmaceuticals
Sector Life Science
Buyer(s) Chiesi Farmaceutici
Sellers(s) Horizon Therapeutics
Deal Type Divestiture
Deal Value 70M USD

Target

Raptor Pharmaceuticals

Novato, California, United States
Raptor Pharmaceutical Corp. is a bio pharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor Pharmaceuticals Corp. was established in 2005 and is headquartered in Novato, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Chiesi Farmaceutici

Parma, Italy
Category Company
Founded 1935
Sector Life Science
DESCRIPTION

Chiesi Farmaceutici is a research-focused international group, with more than 75 years of experience headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas.

DEAL STATS #
Overall 4 of 5
Sector (Life Science) 3 of 4
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-20 Alcala Farma SL

Correos, Spain

Alcala Farma SL is a manufacturer and marketer of own and in-licensed pharmaceuticals, branded generics and OTC products.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-08 Amryt Pharma

Dublin, Ireland

Amryt Pharma is a pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma is based in Dublin, Ireland.

Buy $1.5B

Seller(S) 1

SELLER

Horizon Therapeutics

Dublin, Ireland
Category Company
Founded 2005
Sector Life Science
Employees2,100
Revenue 3.2B USD (2021)
DESCRIPTION

Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-08 River Vision Development

New York, New York, United States

River Vision Development Corp. is a fully human monoclonal antibody (mAb) currently in development for Thyroid Eye Disease (TED), a rare, autoimmune inflammatory disorder. River Vision Development Corp. was founded in 2011 and is based in New York, New York.

Buy $145M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-02 Curzion Pharmaceuticals

San Diego, California, United States

Curzion Pharmaceuticals, Inc. is a development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Curzion Pharmaceuticals was founded in 2019 and is based in San Diego, California.

Buy $45M
Mergr

Product

Company

Legal